Bonalive manufactures and develops bone graft substitutes based on bioactive glass that reduce the need for antibiotics. The company’s technology addresses the growing need to treat infections sustainably, without local antibiotics, they state.

“AMR is not a distant threat; it is already a reality. We need solutions to treat infections without antibiotics, and the most important thing is to focus specifically on preventing infections. In the future, we hope to work more closely with researchers and healthcare professionals in different fields to tackle this global challenge together,” says Marco Hautalahti, CEO of Bonalive.

Finnish product development

The clinical use of Bonalive bioactive glass has been developed in Finland since the 1990s.

At Bonalive’s new factory, production, quality assurance, testing, and product development take place under one roof. This enables the company to better meet international demand. Today, Bonalive operates in 40 countries through direct sales or distributors. The company’s main markets are Europe, South America, and Australia. The company is currently expanding its activities, particularly in the US market.

Bonalive products treat war injuries in Ukraine

In recent years, Bonalive’s solutions have also seen use in Ukraine. Bioactive glass has been used to treat over 300 patients, particularly in cases of severely infected war wounds, describes the company.

“On the front line, wounds become infected quickly, and antibiotics may be less effective. Bonalive’s solutions support bone regeneration and provide a vital antimicrobial alternative in environments where treatment conditions are extremely demanding,” says Hautalahti.